Skip to main content
. Author manuscript; available in PMC: 2009 Jun 9.
Published in final edited form as: Am J Clin Oncol. 2008 Dec;31(6):573–579. doi: 10.1097/COC.0b013e318173a536

Table 3.

Changes in tetramer frequencies to melanoma differentiation antigens

Dose level Antigen reactivity Non-detectable pre- and post-treatment Non-detectable pre-treatment/detectable post treatment Detectable pre-treatment/ non-detectable post treatment Detectable pre-and post treatment
500
(n=2)
MART-1 1 0 1
[0.13↓]
0
gp100 1 1
[↑ 0.16]
0 0
tyrosinase 2 0 0 0
1000
(n=5)
gp100 3 1
[↑ 0.07]
1
[0.06↓ ]
0
MART-1 & tyrosinase 5 0 0 0
1250
(n=2)
gp100 0 0 2
[0.06↓ ;0.05↓]
0
MART-1 & tyrosinase 2 0 0 0
1500
(n=3)
MART-1 0 0 0 3
[0.11↑0.12 ; 0.14↑0.17 ; 0.13↑0.23]
gp100 0 2
[↑ 0.08 ;↑ 0.11]
0 1
[0.08↑0.13]
tyrosinase 0 0 0 3
[0.09↑0.16 ; 0.26↓0.17; 0.20↑0.29]
1750
(n=4)
MART-1 0 0 3
[ 0.08↓ ; 0.07↓ ; 0.05↓]
1
[0.18↓0.10]
gp100 0 0 1
[ 0.06↓]
3
[0.08↑0.11 ; 0.08↓0.07; 0.09↓0.06]
tyrosinase 1 0 0 3
[0.16↓0.06; 0.07↑0.11; 0.10↑0.30]
2000
(n=5)
MART-1 0 0 0 5
[0.06↑0.18; 0.12↑0.14; 0.86↓0.61; 0.16↓0.12; 0.28↓0.22]
gp100 0 0 0 5
[0.15↑0.40; 4.70↑20.1; 0.14↑0.38; 0.11↑0.12; 0.20↑0.68]
tyrosinase 1 1
[↑ 0.18]
3
[0.06↑0.10; 0.50↑1.12; 0.44↓0.16]